<DOC>
	<DOC>NCT02427373</DOC>
	<brief_summary>A multiple-dose, double-blind, randomized, four-week, three-treatment, parallel study in which 66 healthy adult subjects will receive 6 capsules/d, administered as a dose of 1.3 g/d eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) in fish oil ethyl ester (EE), or fish oil triglyceride (TG) or krill oil for a total of 4 weeks. The objective of the study is to compare the oral bioavailability of EPA+DHA in total plasma across the three formulations at the end of the 4 week study.</brief_summary>
	<brief_title>A Parallel Bioavailability Study of Fish Oil-Ethyl Ester Versus Fish Oil-Triglyceride Versus Krill Oil</brief_title>
	<detailed_description />
	<criteria>Healthy, adult female who is neither pregnant nor breastfeeding, or a healthy, adult male with a body mass index (BMI) between 18 and 30 kg/m2 (inclusive), and with a minimum weight of 50 kg (110 lbs). history or presence of diabetes, high triglycerides (≥240 mg/dL), or high cholesterol (≥240 mg/dL); clinically significant abnormal finding on the physical exam, medical history, vital signs, or clinical laboratory results at screening; history or presence of allergic response to omega3fatty acids or sensitivity or allergy to fish or shellfish; history of coagulation disorder or current anticoagulation therapy; has used any nutritional supplements, omega3 supplements, fish oil, chia, krill oil, flaxseed or foods supplemented with omega3s within 3 months prior to the first dose of study medication; has used any prescription medication, except hormonal contraceptive or hormonal replacement therapy, within 14 days prior to the first dose of study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>bioavailability</keyword>
	<keyword>fish oil</keyword>
	<keyword>krill oil</keyword>
</DOC>